For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

Studies doing genome-wide testing can easily ID patients with naturally low neutrophil counts, but nobody's looking at it, ...

The agency maintains that the beta-amyloid-targeting drugs show too limited benefit to justify their cost to the National Health Service.

Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.

NEW YORK – Singapore's Ministry of Health announced this week it will launch a genetic testing program to improve diagnosis of familial hypercholesterolemia (FH) as part of a broader national focus on ...

The companies aim to generate preclinical proof-of-concept data on SRB123 and quickly take it into clinical trials.

Medical ethicists are bringing attention to an early chapter of precision medicine history, an often overlooked aspect of an ...

Trump administration health officials assured drugmakers and researchers at a roundtable hosted by the FDA that they want to ...

The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...